What is NanoMosaic?
NanoMosaic operates at the intersection of nanotechnology and clinical diagnostics. Its core offering, the Tessie platform, utilizes a proprietary chip format embedded with 1.8 billion MosaicNeedles to facilitate high-sensitivity, label-free protein assays. This technology enables researchers to achieve unprecedented multiplexing capabilities and dynamic range, effectively pushing the boundaries of what is possible in biomarker identification. By providing a scalable solution for rapid custom assay development, NanoMosaic serves as a critical infrastructure provider for pharmaceutical and clinical research organizations aiming to improve diagnostic precision and patient outcomes.
How much funding has NanoMosaic raised?
NanoMosaic has raised a total of $42.8M across 2 funding rounds:
Angel/Seed
$2M
Series A
$40.8M
Angel/Seed (2021): $2M with participation from villageglobal.com, Zayn Capital, and VEF
Series A (2021): $40.8M led by Pura Vida Investments, Insight Partners, RA Capital Management, and Time BioVentures
Key Investors in NanoMosaic
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in healthcare and life science companies, utilizing its internal TechAtlas think tank to support scientific and clinical data analysis.
Insight Partners
A global software-focused venture capital and private equity firm that provides operational support and leadership development to its portfolio companies as they scale.
Pura Vida Investments
A specialized hedge fund that invests across all sectors and stages of the healthcare industry, maintaining a focus on both public and private market opportunities.
What's next for NanoMosaic?
With the infusion of recent capital, NanoMosaic is expected to scale its manufacturing capabilities and expand its commercial footprint. The strategic focus will likely center on deepening the adoption of the Tessie platform across global research institutions and diagnostic laboratories. As the company continues to refine its proteomic interrogation capabilities, it is poised to play a pivotal role in the next generation of precision medicine, potentially setting new benchmarks for sensitivity and throughput in the biomarker discovery market. Future milestones will likely involve the integration of its technology into broader clinical workflows, further cementing its position as a leader in the evolving landscape of proteomic diagnostics.
See full NanoMosaic company page
